HMR 3787
Alternative Names: RU 64399Latest Information Update: 10 Feb 2006
At a glance
- Originator sanofi-aventis
- Class Antibacterials; Ketolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 31 Dec 2004 Discontinued - Preclinical for Bacterial infections in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 10 Oct 2002 Preclinical trials in Bacterial infections in France (unspecified route)